Payapps Limited
Total Consideration
$381.0M
3 years of history · ending 2026-01-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2018 | FY2026 |
|---|---|---|
| Federal Statutory Rate | 33.81% | 21.00% |
| State & Local Income Taxes | — | 1.00% |
| Foreign Rate Differential | — | — |
| Other Adjustments | — | — |
| R&D Tax Credits | — | 2.00% |
| SBC (Nondeductible) | — | 4.00% |
| Valuation Allowance Change | — | 1.00% |
| Effective Tax Rate | — | 30.00% |
Cash vs Accrual
| Item | FY2018 | FY2026 |
|---|---|---|
| Income Tax Expense (Accrual) | $9.6M | $479.0M |
| Income Taxes Paid (Cash) | $84.5M | $258.0M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$381.0M
Total Consideration
$122.0M
Total Consideration
$71.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2026-01-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | +$98M | $1M | $97M |
| Facility Closing | Facility Closing | +$2M | — | $2M |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).